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Prescribing in Pregnancy and Breast Feeding 
 
Abstract 
In this article in the series of ‘bite sized’ pharmacology, we will look at the pharmacological 
considerations when prescribing for the pregnant or breast feeding patient. This article will 
illustrate the common issues to consider when prescribing in these groups. Focus will be on 
pharmacokinetics and pharmacodynamics but the types of harm that can occur when 
medications are given in pregnancy will also be discussed. There will also be some 
consideration of prescribing in women of child bearing age. Exercises provided will help you 
apply this knowledge to your prescribing practice.  
 
We must remember as prescribers that a drug has to be: 
 Absorbed into the body fluids and tissues 
 Distributed to its active site 
 Metabolised, primarily by the liver 
 Excreted, primarily by the kidneys 
 
These actions that occur after administration are pharmacokinetics and we shall begin by 
exploring the differences in this population of patient. 
 
Pharmacokinetics is the action of the body on the drugs that we take. It can be broken down 
into four processes as can be seen from table 1. (More detail on each of these processes is 
found in the article on pharmacokinetics in Volume 15, issue3). 
 
 
Table 1- The four pharmacokinetic processes that occur after oral drug administration 
A- Absorption of the drug 
D- Distribution of the drug molecules 
M- Metabolism of the parent drug 
E- Excretion of the drug and its metabolites 
As with all areas of prescribing, it is wise to consider the seven principles of good prescribing 
practice when dealing with all patients 
Prescribing Pyramid (NPC 1999)
 
When considering prescribing in the pregnant or breast feeding woman, it is important to 
remember additional information may need to be gathered by consultation and examination 
and the way that you gather and use this information may be different. We will go on to 
explore the relevant areas of the framework.  
 
Exercise 
Using the BNF, choose a common drug from your area of practice. Review the guidance on 
prescribing in pregnancy and breastfeeding given for the drug in its monograph and reflect on 
how this may affect your prescribing practice. 
 Consider the Patient 
Consideration of the patient should be modified to reflect the additional considerations 
required when prescribing for the patient who may be pregnant, trying to conceive or is 
breastfeeding after the birth of a child. On some occasions women may still be breast feeding 
a child while pregnant with another and this can further complicate prescribing regimes. . The 
main factors to consider in addition to normal consultation and examination are; 
 
• Changes to the normal pharmacokinetic processes 
• The stage of gestation 
• Increased risk to the developing foetus 
• Potential for increased risk of poor compliance 
• Continuation of essential medicines in pregnancy  
• Changing medications during pre-conception period 
 
Changes to Pharmacokinetics in Pregnancy 
 
Absorption 
Absorption of drugs from the oral route can be compromised in certain gastrointestinal conditions that 
can be found in any stage of pregnancy.  
Morning sickness in pregnancy can reduce the amount of drug that is available to be absorbed in the 
gastrointestinal tract if the drug has been given by the oral route. For that reason consideration of the 
level of nausea and vomiting, the frequency and the duration should be done before prescribing by 
this route. Administration times should be targeted at the period when the sickness is at its least or an 
alternative route of administration may need to be sought.  
Indigestion in pregnancy, at all stages of gestation can be problematic to the patient but may also be a 
sign of changes in gastric acid secretion. 
For the most part gastric acid secretion during the gestational period can be decreased and the 
amount of mucus secreted can be increased, both of these things can lead to changes in 
gastric pH. These changes can reduce the absorption of some drugs that are taken by the oral 
route while increasing the absorption of other drugs. It is also known that intestinal transit 
time can be changed changing drug bioavailability, however these changes have little overall 
effect on actual drug bioavailability in the pregnant woman. (Feghali, Venkataramanan & 
Caritis 2015) 
 
Distribution 
Distribution of drugs from the absorbing site to the plasma and then from plasma to cell and 
tissues can be compromised. Plasma proteins play a crucial role in drug distribution and 
bioavailability and they can be reduced in concentration in the pregnant women.  The actual 
number of proteins does not change but as the general circulation increases with 
incorporation of the foetal circulation the concentration drops. This can lead to higher levels 
of ‘free drug’ and a risk of side effects and toxicity as the unbound drug is free to cross the 
placenta. In pre-eclampsia, the low levels of serum albumen can compound this and allow the 
even higher levels of free drug to cross to the foetal circulation. Another factor is the change 
in body composition. There is a change to the body fat and water ratio in that the total body 
water is increased.  
The passage of drugs from the maternal to the foetal circulation can be beneficial, for 
example we can give steroids to the mother for passage to the foetus to promote lung 
maturation if there is significant risk of pre-term delivery. But passage of drug can largely be 
considered to have potential detrimental effects and the highest risk of these is during 
organogenesis in trimester one. (Griffiths and Campbell 2015) 
 
Causes of Foetal Harm 
Harm to the foetus can be divided into two categories; 
• Indirect – due to impact on blood flow 
• Direct due to harmful substance reaching foetus 
 
Types of Harm 
The types of harm that can be identified due to drug or medication use in pregnancy are 
usually linked to the time of gestation the medication is given at; 
• Death and miscarriage – up to week 3 
• Structural Injury – weeks 3-11 e.g. Spina bifida 
• Functional injury – weeks 8-12 
• Retardation of growth – second and third trimester 
Exercise 
Using the BNF, or other drug resource, look up an essential drug you are likely to prescribe 
in practice (for example anticonvulsants or antidiabetic drugs), where the risk to the mother 
in stopping the drug is great. Identify if there are any restrictions on prescribing in pregnancy. 
Reflect on any changes you would need to make to dose or prescribing regimes in light of 
this.  
 
Metabolism 
As we know drug metabolism and biotransformation primarily occurs in the liver. Some 
evidence exist that suggests there is an increased activity of the livers drug metabolising 
enzymes, the cytochrome P450’s, during pregnancy (Isoherranen & Thummel 2013). This 
means that if the enzymes responsible for drug metabolism are increased in activity then they 
will be clearing the drug through the liver ready for excretion at a faster rate. This may affect 
the duration of action of some medications.  This does however seem to be variable between 
women and can also be affected by ethnicity and age (Feghali, Venkataramanan & Caritis 
2015) 
 
Excretion 
Drug excretion is largely carried out by the kidney for expulsion in urine and is dependent on 
glomerular filtration, tubular secretion and tubular reabsorption for maximum efficiency in 
elimination of drugs and metabolites. It is known that the glomerular filtration rate increases 
in pregnancy. This occurs in the first 3 months of gestation and continues until delivery in 
line with the increase in maternal circulation found during term. This means that for drugs 
that are primarily eliminated due to renal excretion then the clearance rate through the kidney 
will be higher and affect duration of action and circulating plasma levels.  
Pharmacokinetic considerations relate to the ‘which strategy’ and ‘choice of product’ areas of 
the prescribing pyramid. 
 
Exercise 
Using the online medicines compendium look up a drug you are likely to prescribe in 
pregnancy and identify its primary route of elimination (hepatic metabolism or renal 
excretion) and reflect upon how the removal of the drug from the body may be affected by 
the state of pregnancy.  
 
Prescribing in the Breast Feeding Woman 
It is known that small or trace amounts of drugs given to a woman can be passed to her 
nursing infant during breast feeding. Lipid soluble, low molecular weight drug molecules are 
more likely to pass into breast milk, due to its high relative fat content, and be passed onto the 
child whose own pharmacokinetic processes may be as yet not fully developed. However 
withholding breast feeding is not a no risk option and the prescriber should be able to assess 
any risk to the child.  
The BNF is an invaluable resource when prescribing in the breast feeding woman as it will 
identify drugs that pose a risk. It classifies the risk as follows 
 Drugs that should be used with caution or are contra-indicated in breast-feeding 
 Drugs that can be given to the mother during breastfeeding because they are present in 
milk in amounts which are too small to be harmful to the infant 
 Drugs that might be present in milk in significant amount but are not known to be 
harmful 
Retrieved from BNF online https://bnf.nice.org.uk/guidance/prescribing-in-breast-
feeding.html 
 
Prescribing in the Woman of Childbearing Age 
For some medications the wariness of prescribing in pregnancy and breast feeding also 
extends to women and girls of childbearing age. A good example of this is the drug valproate.  
This is a drug, previously used in many patients for its anticonvulsant properties but now a 
NICE recommended second line treatment for the prevention of relapse in bipolar disorder 
(NICE 2014). Its known teratogenic effects had led to dose restrictions and prescribing 
cautions, and changing to another drug in planned pregnancy. It even returned to black 
triangle status so that intensive monitoring could be carried out. This monitoring led to the 
banning of prescribing valproate in women and girls of child bearing age unless a pregnancy 
prevention programme is in place in early 2018 after the publication of findings and of audits 
took place (Paton, Cookson, Ferrier, Bhatti, Fagan and Barnes 2018).  
 
 
Exercise 
Using the most current resources you have available, look up sodium valproate and identify 
the risks of prescribing to women and girls of child bearing age. Reflect on the prevalence 
and type of birth defects that can occur and why this drug has now be banned from 
prescription to this patient group unless a pregnancy prevention programme is in place.  
 
Adherence to Medication Regimes 
Compliance with or adherence to medication regimes can be problematic in the pregnant 
woman as she may feel that taking any medication may be detrimental or harmful to the 
baby.  It is important as prescribers that we ensure that the drug benefit to the mother 
outweighs the risk to the developing foetus and that the mother is fully informed about any 
risks in taking medication and the risks of not taking essential medication during pregnancy. 
We should still always try to reach a concordant agreement and this falls under the ‘Negotiate 
a Contract’ section of the prescribing pyramid.   
 
Exercise 
Can you identify drugs in your area of practice that would be essential to continue in 
pregnancy and how you could manage the prescribing of these in a patient who may not be 
compliant due to her perceived risk to the child?  
 
Can we put in some pictures to break the text up a bit?  
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